Breast Cancer Trial, Recruiting NCT07398079 Sponsor: University Hospital, Basel, Switzerland Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07398079
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had breast cancer or a gynaecological cancer (such as ovarian, endometrial, cervical, vulvar, or vaginal cancer), including those whose cancer has come back
  • People who have finished their main cancer treatment, which may have included surgery, radiation, chemotherapy, or a combination of these
  • People aged 18 or older
  • People who are currently on or are planning to start a long-term maintenance treatment lasting more than 3 months during the study period (for example, hormone-blocking therapy, targeted therapies, or immunotherapy) are still eligible to participate
  • People who have had a previous cancer diagnosis are still eligible to participate
  • People who have had previous cancer treatment, including chemotherapy for a prior cancer, are still eligible to participate
  • People who have a stoma are still eligible to participate
  • People who are currently taking part in another experimental drug trial are still eligible to participate
  • People who are using complementary therapies, including mistletoe therapy, are still eligible to participate
  • People who are pregnant are still eligible to participate
  • People who agree to take part and sign a consent form

Who may not be able to join:

  • People who have language difficulties or cognitive (thinking or understanding) challenges that would make it too hard to take part in the study
  • People with serious physical or mental health conditions that would prevent them from participating
  • People who are not able to give their own informed consent to join the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Viola Heinzelmann-Schwarz, Prof. MD, University Hospital of Basel

Phone: +41 61 32 85885

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Basel, Switzerland
Registry
ClinicalTrials.gov
Start date
6 October 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Feasibility of Study Conduct (Composite Outcome)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov